GTx is conducting two phase III studies of enobosarm, a selective androgen receptor modulator (SARM) in lung-cancer related muscle wasting. The company's official guidance is to report results in the third quarter but the data are expected to be announced in August.

The survey says: The enobosarm studies will fail, with 39 percent of respondents predicting negative results. Almost the same number of people -- 38 percent -- had no opinion on the outcome of the studies; while only 24 percent predicted positive results. I predict failure for enobosarm's clinical trials, in line with a recent , bearish column about the drug and its previously conducted phase II study.

Here's the pie chart:

My panel of 12 professional healthcare investors are equally unimpressed with GTx and enobosarm. Seventy-five percent predicted negative results versus 17 percent predicting a positive outcome. One investor chose not to respond.

Here's a look at GTx's stock chart for the past six months: GTXI Chart GTXI data by YCharts

GTx's short interest is relatively modest at just over 3 million shares.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind